Trends of second-line eradication therapy for helicobacter pylori in Japan: A multicenter study in the Tokyo metropolitan area

Daisuke Asaoka, Akihito Nagahara, Takeshi Matsuhisa, Shin ichi Takahashi, Kengo Tokunaga, Takashi Kawai, Kohei Kawakami, Hidekazu Suzuki, Masayuki Suzuki, Toshihiro Nishizawa, Naoto Kurihara, Masayoshi Ito, Hitoshi Sasaki, Fumio Omata, Shigeaki Mizuno, Akira Torii, Toshifumi Ohkusa, Tetsuya Mine, Nobuhiro Sakaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: In Japan, the eradication rate of first-line therapy for Helicobacter pylori (H. pylori) with a proton pump inhibitor (PPI), amoxicillin (AMPC) and clarithromycin (CAM) has been decreasing because of a high prevalence of CAM resistance. A possible decrease of the eradication rate for second-line therapy with a PPI, AMPC and metronidazole (MNZ) is of concern. The aim of this study is to assess the trends in second-line eradication therapy for H. pylori in Japan. Materials and Methods: We accumulated data retrospectively on patients administered second-line eradication therapy for Helicobacter pylori with a PPI, AMPC, and MNZ for 1 week after failure of first-line eradication therapy with a PPI, AMPC and CAM at 15 facilities in the Tokyo metropolitan area in Japan from 2007 to 2011. Trends for second-line eradication rates in modified intention-to-treat (ITT) analyses were investigated. Second-line eradication rates were categorized by three PPIs (rabeprazole (RPZ), lansoprazole (LPZ) or omeprazole (OMZ)) and evaluated. Results: We accumulated data on 1373 patients. The overall second-line eradication rate was 92.4%. Second-line eradication rates in 2007, 2008, 2009, 2010 and 2011 were 97.7, 90.6, 94.5, 91.8 and 91.8%, respectively, with no significant trends revealed. Second-line eradication rates categorized by three PPIs for the entire 5-year period were 91.6, 93.4 and 92.4% (RPZ, LPZ and OPZ, respectively) with no significant differences among the three PPIs. Conclusions: From 2007 to 2011, there were no significant trends in the second-line eradication rates and the rates remained consistently high. From the viewpoint of high prevalence of CAM resistance in Japan, triple therapy with PPI, AMPC and MNZ may be a better strategy for first-line therapy compared to triple therapy with PPI, AMPC and CAM.

Original languageEnglish
Pages (from-to)468-472
Number of pages5
JournalHelicobacter
Volume18
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1

    Fingerprint

Keywords

  • 7-day triple therapy
  • Helicobacter pylori
  • Metonidazole
  • Proton pump inhibitor
  • Second-line therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Infectious Diseases

Cite this

Asaoka, D., Nagahara, A., Matsuhisa, T., Takahashi, S. I., Tokunaga, K., Kawai, T., Kawakami, K., Suzuki, H., Suzuki, M., Nishizawa, T., Kurihara, N., Ito, M., Sasaki, H., Omata, F., Mizuno, S., Torii, A., Ohkusa, T., Mine, T., & Sakaki, N. (2013). Trends of second-line eradication therapy for helicobacter pylori in Japan: A multicenter study in the Tokyo metropolitan area. Helicobacter, 18(6), 468-472. https://doi.org/10.1111/hel.12063